构建纳入SNP交互作用的多基因风险评分预测放疗毒性
该研究基于REQUITE前列腺癌队列(1387例)分析SNP-SNP交互对放疗后晚期毒性的影响,提出纳入交互作用的多基因风险评分PRSi。PRSi在有无毒性患者间分布差异显著,AUC为0.61–0.78,优于经典累加PRS,尤以尿频、血尿、尿流减弱终点为著。
要点
- SNP-allele集风险评分与保护评分可合并为PRSi预测放疗毒性。
- PRSi的AUC为0.61–0.78,优于经典累加PRS。
- 该方法有望将遗传信息纳入正常组织并发症概率模型。
核心结论
- 纳入SNP-SNP交互作用计算放疗毒性多基因风险评分的方法优于经典累加。
- 该方法能更好区分发生与未发生放疗毒性的患者,并有望将遗传信息纳入正常组织并发症概率模型。
研究设计与样本
- 基于REQUITE前列腺癌队列,患者接受外照射放疗并随访2年。
- 分析1387例患者,晚期毒性终点为直肠出血、尿频、血尿、夜尿、尿流减弱。
- 从43个文献识别的SNP中,测试与各毒性关联最强的30%,将队列中≥10%出现的SNP-SNP组合压缩为风险评分RS和保护评分PS,再合并为PRSi,用逻辑回归和AUC评价。
主要发现
- 毒性发生率:直肠出血11.7%、尿频4.0%、血尿5.5%、夜尿7.8%、尿流减弱17.1%。
- RS和PS依毒性终点合并8至15个不同SNP-allele集。
- 有无毒性患者的PRSi分布差异显著,AUC范围为0.61至0.78。
- PRSi优于经典累加PRS,尤其在尿频、血尿和尿流减弱终点。
关键数值与推荐
- SNP-SNP组合在队列中出现频率≥10%才纳入SNP-allele集。
- 从43个文献识别SNP中选取与各毒性关联最强的30%进行测试。
- PRSi的AUC范围为0.61至0.78。
临床怎么用
- 可基于SNP交互作用构建PRSi,用于前列腺癌放疗后晚期毒性风险分层。
- PRSi有望整合入正常组织并发症概率模型,辅助个体化放疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To identify the effect of single nucleotide polymorphism (SNP) interactions on the risk of toxicity following radiotherapy (RT) for prostate cancer (PCa) and propose a new method for polygenic risk score incorporating SNP-SNP interactions (PRSi). MATERIALS AND METHODS: Analysis included the REQUITE PCa cohort that received external beam RT and was followed for 2 years. Late toxicity endpoints were: rectal bleeding, urinary frequency, haematuria, nocturia, decreased urinary stream. Among 43 literature-identified SNPs, the 30% most strongly associated with each toxicity were tested. SNP-SNP combinations (named SNP-allele sets) seen in ≥10% of the cohort were condensed into risk (RS) and protection (PS) scores, respectively indicating increased or decreased toxicity risk. Performance of RS and PS was evaluated by logistic regression. RS and PS were then combined into a single PRSi evaluated by area under the receiver operating characteristic curve (AUC). RESULTS: Among 1,387 analysed patients, toxicity rates were 11.7% (rectal bleeding), 4.0% (urinary frequency), 5.5% (haematuria), 7.8% (nocturia) and 17.1% (decreased urinary stream). RS and PS combined 8 to 15 different SNP-allele sets, depending on the toxicity endpoint. Distributions of PRSi differed significantly in patients with/without toxicity with AUCs ranging from 0.61 to 0.78. PRSi was better than the classical summed PRS, particularly for the urinary frequency, haematuria and decreased urinary stream endpoints. CONCLUSIONS: Our method incorporates SNP-SNP interactions when calculating PRS for radiotherapy toxicity. Our approach is better than classical summation in discriminating patients with toxicity and should enable incorporating genetic information to improve normal tissue complication probability models.
引用
- Franco NR, Massi MC, Ieva F, et al. Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. Radiother Oncol. 2021. PMID: 33838170. doi:10.1016/j.radonc.2021.03.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。